Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977311 | 0.89 | RAB9A (0.51) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL4088965 | 0.87 | CYP1A2 (0.62) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL3977137 | 0.86 | RAB9A (0.49) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL3984275 | 0.83 | CYP1A2 (0.54) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL13612898 | 0.82 | CYP1A2 (0.54) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL3977553 | 0.82 | RAB9A (0.71) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL3977995 | 0.81 | CYP1A2 (0.52) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL3984000 | 0.81 | RAB9A (0.49) | RAB9ACYP1A2CYP3A4POLBNPC1 | |
| SCHEMBL3978108 | 0.80 | CYP1A2 (0.77) | RAB9ACYP1A2CYP3A4NPC1KMT2A | |
| SCHEMBL3980301 | 0.80 | CYP1A2 (0.54) | RAB9ACYP1A2CYP3A4POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | claimed |
| CN-101522184-A | Thiourea compounds | NAT HEALTH RESEARCH INSTITUTES (CN) | 2009-09-02 | — | — | CN | disclosed |
| EP-2056810-A2 | THIOUREA COMPOUNDS | National Health Research Institutes (TW) | 2009-05-13 | — | — | EP | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080113975-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-05-15 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| US-20080096875-A1 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-04-24 | — | — | US | disclosed |
| WO-2008022204-A2 | THIOUREA COMPOUNDS | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-02-21 | — | — | WO | disclosed |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096875-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, ETV6 | RAB9A 2434/4885CYP1A2 555/4885CYP3A4 409/4885 |
| US-20080009486-A1 | SPIROINDOLINONE DERIVATIVES | RB1, PKD1, KRAS | RAB9A 510/4885CYP1A2 782/4885CYP3A4 756/4885 |
| US-20080113975-A1 | THIOUREA COMPOUNDS | TPMT, HAVCR2, EIF2AK2 | RAB9A 2430/4885CYP1A2 556/4885CYP3A4 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.